Follow all directions on your medicine label and package. Aclidinium is a dry powder inhaler used twice daily. Aclidinium bromide drug bnf content published by nice. Each delivered dose contains approximately 11 mg lactose as monohydrate. Evidence shows that it can improve quality of life and prevent hospitalization in those with copd. Aclidinium bromide, the active component of tudorza pressair is an anticholinergic with specificity for muscarinic receptors. Aclidinium bromide is a longacting, inhaled muscarinic antagonist lama approved in the us on july 24, 2012 as a maintenance treatment for chronic obstructive pulmonary disease copd evidence shows that it can improve quality of life and prevent hospitalization in those with copd. Indications, dose, contraindications, sideeffects, interactions, cautions, warnings and other safety information for aclidinium bromide. Duaklir pressair aclidinium bromide and formoterol fumarate. Combining this drug with acetylcholinesterase inhibitors or anticholinergic medications can cause negative interactions. Approved drug products containing aclidinium bromide listed in the fda orange book. Fda requests more data on forest labs copd drug combo. Aclidinium is used to prevent bronchospasm in adults with chronic bronchitis, emphysema, or other forms of copd chronic obstructive pulmonary disease.
Appropriate studies performed to date have not demonstrated geriatricspecific problems that would limit the usefulness of inhaled aclidinium in the. Food and drug administration fda has issued a request for more information regarding questions related to chemistry, manufacturing, and control cmc of its fixed dose combination of aclidinium and formoterol. C indications longterm maintenance treatment of bronchospasm associated with copd, including chronic bronchitis and emphysema. People with moderate copd stage 2people with severe copd stage 3 who have no more than one flareup.
The fda approval of duaklir pressair gives copd patients a new. The fda deemed aclidinium safe and effective on the basis of 3 randomized, placebocontrolled, confirmatory clinical trials involving 1276 patients aged 40. Aclidinium definition of aclidinium by medical dictionary. Aclidinium is a longacting inhibitor of muscarinic receptors with bronchodilatory effects comparable to those of tiotropium.
Tudorza pressair is less popular than other anticholinergics. Aclidinium may also be used for purposes not listed in this medication guide. However, increased incidences of additional liver lobes 35%, as compared to 0% in the control group, were observed at approximately 1,400 times the rhdd based on summed aucs of aclidinium bromide and its. Full text clinical use of aclidinium in patients with. Tudorza pressair aclidinium is used to treat chronic obstructive pulmonary disease, including emphysema and chronic bronchitis. Copd tudorza pressair aclidinium bromide inhalation powder is an anticholinergic indicated for the longterm maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease. References aclidinium bromide tudorza genuair ncbi. Oct 15, 2019 aclidinium is prescribed to help ease the longterm symptoms of cough, wheeze and breathlessness in adults with chronic obstructive pulmonary disease. Forest laboratories and almirall announce fda approval of tudorza. Aclidinium is prescribed to help ease the longterm symptoms of cough, wheeze and breathlessness in adults with chronic obstructive pulmonary disease.
Almirall submitted an maa to the ema a month later. The fda approval of duaklir pressiar was based on a clinical development program that included three dose ranging trials, one active and two. Fda approves duaklir pressair aclidiniumformoterol for patients. To discuss an alternative approach, contact the office of generic drugs. Each delivered dose the dose leaving the mouthpiece contains 396 micrograms of aclidinium bromide equivalent to 340 micrograms of aclidinium and 11. Apr 10, 2014 fda requests more data on forest labs copd drug combo by estel grace masangkay forest laboratories and partner almirall s.
In early 2015, the institute for quality and efficiency in health care iqwig, germany looked into the advantages and disadvantages of the drug combination aclidinium bromide and formoterol for the treatment of copd when compared with the standard therapies. Aclidinium bromide 400 mcgactuation breath activated powder inhaler side effects by likelihood and severity common side effects if experienced, these tend to have a less severe expression. Pressair aclidinium bromide inhalation powder for the longterm. Aclidinium bromide is a synthetic, quaternary ammonium compound, chemically described as 1azoniabicyclo2. Apr 15, 2019 aclidinium bromide, the active component of tudorza pressair is an anticholinergic with specificity for muscarinic receptors. Eklira genuair astrazeneca, bretaris genuair berlinchemie. The fda has approved the tudorza pressair aclidinium bromide dry powder inhaler for the treatment of copd. It is important for your healthcare provider to be aware of all other medications, vitamins, and supplements you are taking before you can begin treatment with aclidinium. Aclidinium ascent study design journal of copd foundation. An fda advisory committee has voted to approve twicedaily aclidinium for copd, but says more research is needed to study safety issues further. Easy to read fda package insert, drug facts, dosage and administration, and adverse effects for tudorza pressair aclidinium.
Make sure you know how to use the inhaler properly. Aclidinium belongs to a class of drugs known as anticholinergics, and formoterol belongs to a class of drugs known as longacting beta agonists labas. Tudorza pressair aclidinium bromide inhalation powder is an anticholinergic indicated for the longterm maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease copd, including chronic bronchitis and emphysema. The fda approval of tudorza pressair was based on a doseranging trial trial a for nominal dose selection and three confirmatory trials. However, it does not appear to affect the risk of death or the frequency steroids are needed.
Aclidinium bromide reduced pup weights when pregnant rats continued inhalation administration through lactation at 5 times the mrhdid. Use the inhaler regularly, each morning and evening. Appropriate studies have not been performed on the relationship of age to the effects of inhaled aclidinium in the pediatric population. Last week, the fda approved aclidinium bromide tudorza pressair as a daily inhaler treatment for chronic obstructive pulmonary disease copd, the agency announced in a press release. Aclidinium bromide inhalation should also be used with caution in patients with severe milk protein hypersensitivity, as the inhaler powder contains lactose which may contain milk proteins. Aclidinium bromide complete drug information, side effects. Characterization of aclidinium bromide, a novel inhaled muscarinic. Apr 15, 2019 tudorza pressair aclidinium bromide inhalation powder is an anticholinergic indicated for the longterm maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. The dpi will be distributed by forest pharmaceuticals, a division of forest laboratories, which licensed us rights to the product from almirall. Aclidinium bromide is an inhaled lama approved for the longterm maintenance treatment of copdassociated bronchospasm, including chronic bronchitis and emphysema. Aclidiniumformoterol fixed combination dose finding study the safety and scientific validity of this study is the responsibility of the study sponsor and investigators.
Forest says that it expects wholesalers to have the product in the fourth quarter of 2012. Maintenance treatment of copd in patients with moderate to severe disease, regular treatment with a longacting bronchodilator can improve lung. The pharmacokinetic properties of aclidinium bromide in patients with moderate to severe copd appear to be similar in patients aged 4059 years and in patients aged. Eklira genuair 322 micrograms inhalation powder summary of. Aclidinium is used as maintenance treatment in patients with chronic obstructive pulmonary disease copd, a lung disease that also includes chronic bronchitis swelling of the tubes leading to the lungs or emphysema damage to the air sacs in the lungs. Clinical potential of aclidinium bromide in chronic. The global initiative for chronic obstructive lung disease gold guidelines provide evidencebased recommendations for the. Full text clinical use of aclidinium in patients with copd.
Jul 23, 2012 the fda has approved the tudorza pressair aclidinium bromide dry powder inhaler for the treatment of copd. Chronic obstructive pulmonary disease copd is the sixthleading cause of death in the us. Common and rare side effects for aclidinium bromide inhalation. Effects of aclidinium bromide on embryofetal development were examined in rats and rabbits. Mcid threshold of a 4unit change data not shown in this document. Action acts as an anticholinergic by inhibiting the m3. How to use aclidinium bromide 400 mcgactuation breath activated powder inhaler. Compare prices, print coupons and get savings tips for aclidinium tudorza pressair and other copd drugs at cvs, walgreens, and other pharmacies. Current clinical management guidelines support regular use of an inhaled. Ask your nurse, doctor or pharmacist to show you, if you are unsure. Forest licensed us rights to aclidinium bromide, an inhaled longacting antimuscarinic agent, from almirall. Aclidinium side effects, dosage, interactions drugs. Aclidinium bromide complete drug information, side.
Clinical use of aclidinium in patients with copd debra j reid, alexa a carlsondepartment of pharmacy practice, northeastern university, school of pharmacy, boston, ma, usaabstract. Aclidinium bromide will be marketed as tudorza pressair by forest pharmaceuticals, a subsidiary of forest laboratories. Tudorza pressair aclidinium bromide inhalation powder company. There are currently no generic alternatives to tudorza pressair. People with moderate copd stage 2people with severe copd stage 3 who have no more. Efficacy and safety of twicedaily aclidinium bromide in copd patients. It consists of aclidinium bromide, a longacting muscarinic antagonist, and formoterol, a longacting. Aclidinium is a longacting muscarinic antagonist or anticholinergic bronchodilator that will compete with tiotropium spiriva, which was launched in 2004 and until now was the only available. You are permitted to make copies of this document for noncommercial. Aclidinium is used to prevent bronchospasm in adults with chronic bronchitis, bysema, or other forms of copd chronic obstructive pulmonary disease. Aclidiniumformoterol trade names duaklir and brimica is a combination drug for inhalation, used in the management of chronic obstructive pulmonary disease copd.
Fda panel recommends twicedaily aclidinium for copd. Circassia sells its novel, marketleading niox asthma management. The ers total score is an aggregate of three domains. The fda approval of aclidinium bromide was based on 4 clinical trials, including a doseranging study for nominal dose selection and 3 confirmatory studies. Aclidinium inhalation route before using mayo clinic. Tudorza pressair aclidinium bromide inhalation powder. Aclidinium is used as a long term treatment to prevent wheezing, shortness of breath, coughing, and chest tightness in patients with chronic obstructive pulmonary disease copd, a group of diseases that affect the lungs and airways such as chronic bronchitis swelling of the air passages that lead to the lungs and emphysema damage to air sacs in the lungs. Aclidinium bromide eklira genuair is an inhaled longacting muscarinic antagonist lama for maintenance bronchodilator treatment to relieve symptoms in adults. Us food and drug administration approves duaklir pressair. The fda deemed aclidinium safe and effective on the basis of 3 randomized, placebocontrolled, confirmatory clinical trials involving 1276 patients aged 40 years or older with copd. The fda has approved aclidinium bromide tudorza pressair forest, an orallyinhaled longacting anticholinergic, for longterm maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease copd. Aclidinium bromide demonstrated kinetic linearity and a timeindependent pharmacokinetic behaviour in the therapeutic range. Aclidinium bretaris genuair for chronic obstructive. Aclidiniumformoterol fixed combination dose finding study.
Aclidinium bromide fda orange book approved drug product. Aclidinium is structurally similar to atropine, and as such, crosssensitivity may be possible. Listing a study does not mean it has been evaluated by the u. Aclidinium bromide is a longacting anticholinergic bronchodilator approved by the fda in 2012 for use in the management of chronic obstructive pulmonary disease copd which includes chronic bronchitis and emphysema. Aclidinium bromide is a longacting, inhaled muscarinic antagonist lama approved in the us on july 24, 2012 as a maintenance treatment for chronic obstructive pulmonary disease copd. Tudorza pressair aclidinium bromide inhalation powder is. Aclidinium, an inhaled, longacting antimuscarinic agent, has been developed as a twicedaily maintenance treatment for chronic obstructive pulmonary disease copd.
Aclidinium was simultaneously approved in europe, where it was codeveloped by spains leading drugmaker, almirall. Aclidinium bromide is an inhaled antimuscarinic bronchodilator recently approved in the us and europe for stable copd. Eklira genuair 322 micrograms inhalation powder summary. Aclidinium bromide inn is a longacting, inhaled muscarinic antagonist lama approved in. Instruct patient in proper use of inhaler and to take medication as directed. The companies submitted the new drug application to the fda at the end of june 2011. May 04, 2015 in early 2015, the institute for quality and efficiency in health care iqwig, germany looked into the advantages and disadvantages of the drug combination aclidinium bromide and formoterol for the treatment of copd when compared with the standard therapies. The exactrespiratory symptoms ers questionnaire was completed every evening the ers scale is an instrument comprising a subset of exact items to test the effect of treatment on the severity of respiratory symptoms in stable copd eleven of the 14items of the exact questionnaire provides information about copd symptoms. Aclidinium bromide tudorza pressair for copd the medical. Aclidinium bromide eklira genuair tudorza genuair cas. Food and drug administration fda has issued a request for more information regarding questions related to chemistry, manufacturing, and control cmc of its fixed dose combination of aclidinium. When aclidinium is administered concurrently with other inhalation medications, administer adrenergic bronchodilators first, followed by aclidinium, then corticosteroids. You may report side effects to fda at 1800fda1088 or at. Mathioudakis, in side effects of drugs annual, 2014.
The companies said that a type c meeting with the fda is going to be set. Aclidinium bromide an overview sciencedirect topics. Mar 29, 2012 forest licensed us rights to aclidinium bromide, an inhaled longacting antimuscarinic agent, from almirall. Aclidinium inhalation route description and brand names. The good safety and tolerability profile of aclidinium was confirmed in the longerterm studies, lasmd35 and the accord copd i extension table 1. Side effects of tudorza pressair aclidinium bromide. Tudorza pressair aclidinium bromide inhalation powder is an anticholinergic indicated for the longterm maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. Fda approves tudorza pressair aclidinium bromide dpi. Learn about aclidinium bromide from patients first hand experiences and trusted online health resources, including dosage, side effects and interactions. Both drugs work by relaxing the muscles around the airways in the lungs so they open up to make breathing easier. You may report side effects to fda at 1800 fda 1088 or at. Aclidinium is indicated for longterm maintenance treatment and is not indicated for acute exacerbations of copd. Treatment with the approved dosage of aclidinium 400. Aclidinium bromide is an inhalation powder promoted by forest pharmaceuticals in the us under the trade name tudorza pressair.
370 87 620 474 1260 322 372 749 347 1516 656 456 247 563 92 1468 376 78 1271 1547 1126 1413 709 674 1188 1488 128 37 361 727 939 1164 180 823 567 1317 1293 583 1324 704